1d
Transpire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and ...
Recently, the U.S. Food and Drug Administration (FDA) approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older.
The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results